Holiday Sale — Get 40% off Vantage for yourself or as a gift

Published 20 hours ago • loading... • Updated 20 hours ago

Retina Biotech Raises $184M in Stock Sale as Late-Stage Drug Trials Loom

Summary by stocktitan.net

Kodiak sells 8M shares at $23, raising about $184M before fees. The deal includes 1.04M extra shares from underwriters’ fully exercised option.

24 Articles

24 Articles

Montana Standard

+23 Reposted by 23 other sources

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000…

20 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources24

Leaning Left2Leaning Right0Center9Last Updated26 minutes agoBias Distribution

82% Center

Bias Distribution

82% of the sources are Center

82% Center

+4

Untracked bias

+4

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Helena Independent Record broke the news in Helena, United States 20 hours ago on Friday, December 19, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics